Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Abstract A44: Checkpoint inhibition of adaptive immunity by IL-9 can be disrupted to achieve rapid T cell sensitization and rejection of progressive tumor challenges
Cohen, Peter A. , Gendler, Sandra , Hoelzinger, Dominique B. , Dominguez, Ana Lucía

Cancer Immunology Research | October 16, 2015 | Volume: 3 | Issue: 10_Supplement | Pages: A44-A44

10.1158/2326-6074.tumimm14-a44 Get It

Abstract Interleukin 9 (IL-9), the signature Th9 cytokine, is associated with T regulatory cell function, parasite expulsion and allergic airway inflammation. Because IL-9 can promote a tolerogenic/immunosuppressive environment, we used IL-9 knock-out (IL-9ko) mice to estimate the role of endogenous IL-9 in the biology of two aggressive breast cancers, TUBO and 4T1, and CT26 a colon carcinoma. Merely eliminating endogenous IL-9 enabled efficient sensitization of host T cells leading to early rejection of growing tumors. Duplicate tumor challenges simply grew progressively in wildtype mice. Interestingly, tumor rejection occurred without additional vaccines or immunomodulatory therapies. The IL-9ko mice acquired immunologic memory, which actively protected from residual disease and tumor rechallenges. The ability of a normally lethal tumor challenge to stimulate an enduring therapeutic response in IL-9ko mice was linked to the activation of CD8+ T cells, as IL-9ko mice failed to be cured if either CD8+ or CD4+ T cells were depleted. Importantly, T cells from tumor-rejecting IL-9ko mice retained effector competence in wildtype mice, and treatments with neutralizing anti-IL-9 significantly slowed tumor progression in wildtype mice. IL-9 inhibits the immune system's ability to prime effective immunological memory after exposure to growing tumor; it therefore functions as a checkpoint inhibitor of adaptive immunity. Optimization of IL-9 neutralization may play a unique role in immunotherapy. Citation Format: Dominique B. Hoelzinger, Ana Lucia Dominguez, Peter A. Cohen, Sandra J. Gendler. Checkpoint inhibition of adaptive immunity by IL-9 can be disrupted to achieve rapid T cell sensitization and rejection of progressive tumor challenges. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr A44.
Abstract A41: Galectin-9 has tumor promoting properties that may be targetable in metastatic melanoma
Nevala, Wendy K. , Enninga, Elizabeth Ann L. , Markovic, Svetomir N.

Cancer Immunology Research | October 16, 2015 | Volume: 3 | Issue: 10_Supplement | Pages: A41-A41

10.1158/2326-6074.tumimm14-a41 Get It

Abstract Introduction: Galectin-9 (Gal-9) is a carbohydrate-binding protein that interacts with T-cell immunoglobulin mucin 3 (TIM3) to modulate immune homeostasis. The Gal-9/TIM3 interaction down regulates activated T cells which promotes tumor growth, much like program death 1 (PD-1) and its ligand (PD-L1). Still, the effect Gal-9 has on the immune environment of melanoma patients is weakly understood. This study focuses on the role of Gal-9 in immunoregulation of healthy persons and metastatic melanoma patients. Methods: Soluble Gal-9 levels were determined from plasma collected from patients and healthy persons using standard ELISA methods. Proliferation and apoptosis of cells in the presence and absence of Gal-9 was determined by mixed lymphocyte reactions and Tunnel staining. Supernatants from these reactions were collected and run using a cytokine bead assay to determine changes in immune parameters with and without Gal-9. Results: Soluble Gal-9 was significantly higher in metastatic melanoma patients compared to healthy controls (3929 vs. 877 pg/mL, p=0.0003 respectively). In the presence of Gal-9, the proliferative effect of an allostimulus could be overridden until the level of responder cells to stimulator cells was 4:1. Using an apoptosis assay, Gal-9 was found to increase the level of cellular apoptosis; however, apoptosis was decreased as the allostimulus increased. Healthy cells incubated with Gal-9 were found to increase secretion of growth factors (EGF and FGF-2), chemokines (CXCL1, CXCL8, CCL2 and CCL3), T helper 1 cytokines (IFN-g and IL-7) which have shown tumor promoting affects and T helper 2 cytokines (IL-13 and IL-4). Conclusions: Gal-9 may potentially play a role in suppressing anti-tumor immunity. This suggests the use of a Gal-9 neutralizing antibody for therapeutic benefit in melanoma. Citation Format: Elizabeth Ann L. Enninga, Wendy K. Nevala, Svetomir N. Markovic. Galectin-9 has tumor promoting properties that may be targetable in metastatic melanoma. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr A41.
Heterogeneity of the midbrain dopamine system
Hassan, Anhar , Benarroch, Eduardo E.

Neurology | October 16, 2015 | Volume: 85 | Issue: 20 | Pages: 1795-1805

10.1212/wnl.0000000000002137 | PMID 26475693 Get It

New Pharmacological Strategies to Increase cGMP
Buglioni, Alessia , Burnett, John C.

Annual Review of Medicine | October 16, 2015 | Volume: 67 | Issue: 1 | Pages: 229-243

10.1146/annurev-med-052914-091923 | PMID 26473417 Get It

The Computational Fluid Dynamics Rupture Challenge 2013—Phase II: Variability of Hemodynamic Simulations in Two Intracranial Aneurysms
Berg, Philipp , Roloff, Christoph, Beuing, Oliver , Voß, Samuel , Sugiyama, Shin‐ichiro , Aristokleous, Nicolas , Αnayiotos, Αndreas , Ashton, Neil , Revell, Alistair , Bressloff, Neil W. , Brown, Alistair, Chung, Bong Jae , Copelli, Gabriele, Fu, Wenyu , Geers, Arjan J. , Hodis, Simona , Dragomir‐Daescu, Dan , Nordahl, Emily Rose, Suzen, Yildirim , Khan, Muhammad Owais , Valen‐Sendstad, Kristian , Kono, Kenichi , Menon, Prahlad G. , Albal, Priti G., Mierka, Otto , Münster, Raphael , Bonnefous, Odile , Osman, Jan , Goubergrits, Leonid , Pallarès, Jordi , Cito, Salvatore , Passalacqua, Alberto , Pişkin, Şenol , Pekkan, Kerem , Ramalho, Susana, Marques, N. P. C. , Sanchi, Stéphane, Schumacher, Kristopher R., Sturgeon, Jess, Švihlová, Helena , Hron, J. , Usera, Gabriel , Mendina, Mariana , Xiang, Jianping , Steinman, David A. , Cebral, Juan R. , Qiao, Aike , Morales, Hernán G. , Meng, Hui , Janiga, Gábor , Hron, Jaroslav , Švihlová, Helena

Journal of Biomechanical Engineering | October 16, 2015 | Volume: 137 | Issue: 12 | Pages: No page available

10.1115/1.4031794 | PMID 26473395 Get It

With the increased availability of computational resources, the past decade has seen a rise in the use of computational fluid dynamics (CFD) for medical applications. There has been an increase in the application of CFD to attempt to predict the rupture of intracranial aneurysms, however, while many hemodynamic parameters can be obtained from these computations, to date, no consistent methodology for the prediction of the rupture has been identified. One particular challenge to CFD is that many factors contribute to its accuracy; the mesh resolution and spatial/temporal discretization can alone contribute to a variation in accuracy. This failure to identify the importance of these factors and identify a methodology for the prediction of ruptures has limited the acceptance of CFD among physicians for rupture prediction. The International CFD Rupture Challenge 2013 seeks to comment on the sensitivity of these various CFD assumptions to predict the rupture by undertaking a comparison of the rupture and blood-flow predictions from a wide range of independent participants utilizing a range of CFD approaches. Twenty-six groups from 15 countries took part in the challenge. Participants were provided with surface models of two intracranial aneurysms and asked to carry out the corresponding hemodynamics simulations, free to choose their own mesh, solver, and temporal discretization. They were requested to submit velocity and pressure predictions along the centerline and on specified planes. The first phase of the challenge, described in a separate paper, was aimed at predicting which of the two aneurysms had previously ruptured and where the rupture site was located. The second phase, described in this paper, aims to assess the variability of the solutions and the sensitivity to the modeling assumptions. Participants were free to choose boundary conditions in the first phase, whereas they were prescribed in the second phase but all other CFD modeling parameters were not prescribed. In order to compare the computational results of one representative group with experimental results, steady-flow measurements using particle image velocimetry (PIV) were carried out in a silicone model of one of the provided aneurysms. Approximately 80% of the participating groups generated similar results. Both velocity and pressure computations were in good agreement with each other for cycle-averaged and peak-systolic predictions. Most apparent “outliers” (results that stand out of the collective) were observed to have underestimated velocity levels compared to the majority of solutions, but nevertheless identified comparable flow structures. In only two cases, the results deviate by over 35% from the mean solution of all the participants. Results of steady CFD simulations of the representative group and PIV experiments were in good agreement. The study demonstrated that while a range of numerical schemes, mesh resolution, and solvers was used, similar flow predictions were observed in the majority of cases. To further validate the computational results, it is suggested that time-dependent measurements should be conducted in the future. However, it is recognized that this study does not include the biological aspects of the aneurysm, which needs to be considered to be able to more precisely identify the specific rupture risk of an intracranial aneurysm.
MDS research criteria for prodromal Parkinson's disease
Berg, Daniela , Bloem, Bastiaan R. , Dubois, Bruno, Gasser, Thomas , Halliday, Glenda M. , Joseph, Lawrence , Lang, Anthony E. , Liepelt‐Scarfone, Inga , Litvan, Irene , Marek, Kenneth , Oertel, Wolfgang H. , Olanow, C. Warren , Deuschl, Günther , Postuma, Ronald B. , Adler, Charles H. , Chan, Piu , Goetz, Christopher G. , Obeso, Jose Angel , Poewe, Werner H , Stern, Matthew , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Litvan, Irene

Movement Disorders | October 16, 2015 | Volume: 30 | Issue: 12 | Pages: 1600-1611

10.1002/mds.26431 | PMID 26474317 Get It

ABSTRACT This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease‐modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available. © 2015 International Parkinson and Movement Disorder Society
MDS clinical diagnostic criteria for Parkinson's disease
Berg, Daniela , Olanow, C. Warren , Oertel, Wolfgang H. , Marek, Kenneth , Litvan, Irene , Lang, Anthony E. , Halliday, Glenda M. , Gasser, Thomas , Dubois, Bruno, Bloem, Bastiaan R. , Deuschl, Günther , Postuma, Ronald B. , Stern, Matthew , Poewe, Werner H , Obeso, Jose Angel , Goetz, Christopher G. , Chan, Piu , Adler, Charles H. , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Litvan, Irene

Movement Disorders | October 16, 2015 | Volume: 30 | Issue: 12 | Pages: 1591-1601

10.1002/mds.26424 | PMID 26474316 Get It

AbstractThis document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances. © 2015 International Parkinson and Movement Disorder Society
The fate of cranial neuropathy after flow diversion for carotid aneurysms
Brown, Benjamin L. , Miller, David A. , Brasiliense, Leonardo B.C. , Ringer, Andrew J. , Sauvageau, Eric , Powers, Ciarán J. , Hoit, Daniel , Siddiqui, Adnan H. , Hopkins, L. Nelson , Rodríguez‐Mercado, Rafael, Veznedaroglu, Erol, Binning, Mandy J., Aguilar‐Salinas, Pedro , Boulos, Alan S. , Lopes, Demetrius K. , Tawk, Rabih G. , Arthur, Adam Stephen , Snyder, Kenneth V. , Levy, Elad I. , Cuellar, Hugo , Mocco, J , Yamamoto, Junichi , Hanel, Ricardó A. , Siddiqui, Adnan H

Journal of Neurosurgery | October 16, 2015 | Volume: 124 | Issue: 4 | Pages: 1107-1113

10.3171/2015.4.jns142790 | PMID 26473786 Get It

OBJECT The authors sought to determine whether flow diversion with the Pipeline Embolization Device (PED) can approximate microsurgical decompression in restoring function after cranial neuropathy following carotid artery aneurysms. METHODS This multiinstitutional retrospective study involved 45 patients treated with PED across the United States. All patients included presented between November 2009 and October 2013 with cranial neuropathy (cranial nerves [CNs] II, III, IV, and VI) due to intracranial aneurysm. Outcome analysis included clinical and procedural variables at the time of treatment as well as at the latest clinical and radiographic follow-up. RESULTS Twenty-six aneurysms (57.8%) were located in the cavernous segment, while 6 (13.3%) were in the clinoid segment, and 13 (28.9%) were in the ophthalmic segment of the internal carotid artery. The average aneurysm size was 18.6 mm (range 4–35 mm), and the average number of flow diverters placed per patient was 1.2. Thirty-eight patients had available information regarding duration of cranial neuropathy prior to treatment. Eleven patients (28.9%) were treated within 1 month of symptom onset, while 27 (71.1%) were treated after 1 month of symptoms. The overall rate of cranial neuropathy improvement for all patients was 66.7%. The CN deficits resolved in 19 patients (42.2%), improved in 11 (24.4%), were unchanged in 14 (31.1%), and worsened in 1 (2.2%). Overtime, the rate of cranial neuropathy improvement was 33.3% (15/45), 68.8% (22/32), and 81.0% (17/21) at less than 6, 6, and 12 months, respectively. At last follow-up, 60% of patients in the isolated CN II group had improvement, while in the CN III, IV, or VI group, 85.7% had improved. Moreover, 100% (11/11) of patients experienced improvement if they were treated within 1 month of symptom onset, whereas 44.4% (12/27) experienced improvement if they treated after 1 month of symptom onset; 70.4% (19/27) of those with partial deficits improved compared with 30% (3/10) of those with complete deficits. CONCLUSIONS Cranial neuropathy caused by cerebral aneurysm responds similarly when the aneurysm is treated with the PED compared with open surgery and coil embolization. Lower morbidity and higher occlusion rates obtained with the PED may suggest it as treatment of choice for some of these lesions. Time to treatment is an important consideration regardless of treatment modality.
Characteristics of Dynamic Magnetic Resonance Image Enhancement in Prolactinomas Resistant to Dopamine Agonist Therapy
Guo, Qinghua , Chang, Alice Y. , Erickson, Dana , Erickson, Bradley J.

Journal of Investigative Medicine | October 16, 2015 | Volume: 63 | Issue: 3 | Pages: 529-533

10.1097/jim.0000000000000138 | PMID 25551412 Get It

Objective The objective of this study was to determine whether dynamic magnetic resonance imaging (dMRI) enhancement parameters could predict dopamine agonist (DA) resistance in prolactinomas. Methods We retrospectively identified patients with prolactinomas who were treated with DA and underwent dMRI from 2001 through 2012 at Mayo Clinic (Rochester, MN). Intensities of the adenoma and pituitary gland were measured by drawing regions of interest on the images. Enhancement ratio, enhancement peak, prepeak slope (PPS), and enhancement time were compared between DA-resistant and DA-responsive groups, between DA-treated and DA-naive groups, and between the first and follow-up dMRIs. Results We identified 49 patients with prolactinomas, with 6 (12.2%) showing DA resistance. Thirty-seven patients (75.5%) underwent dMRI while receiving treatment, 12 (25.5%) underwent dMRI before starting therapy, and 10 (20.4%) had follow-up dMRI after DA therapy. The PPS of the tumor was higher in the treatment-resistant group versus the responsive group (mean [SD], 4.42 [3.19] vs 2.65 [1.59]; P = 0.03), whereas no difference was noted in the pituitary gland (5.79 [2.21] vs 4.06 [2.48]; P = 0.11). Logistic regression analysis indicated that tumor PPS was associated with DA resistance (odds ratio, 1.71; 95% confidence interval, 1.07–3.27; P = 0.02). Conclusions Dynamic MRI with PPS analysis potentially can be used early in the treatment course to evaluate DA resistance in pituitary prolactinomas.
Coronary Endothelial Dysfunction in Women with Type 2 Diabetes Measured by Coronary Phase Contrast Flow Velocity Magnetic Resonance Imaging
Maroules, Christopher D. , Chang, Alice Y. , Kotys-Traughber, Melanie, Peshock, Ronald M.

Journal of Investigative Medicine | October 16, 2015 | Volume: 63 | Issue: 7 | Pages: 856-861

10.1097/jim.0000000000000226 | PMID 26230492 Get It

Objective The aim of this study was to determine if differences in coronary endothelial function are observed between asymptomatic women with type 2 diabetes mellitus (DM) and control subjects using coronary phase contrast flow velocity magnetic resonance imaging in response to cold pressor stress, an established endothelium-dependent vasodilatory stress. Methods Phase contrast flow velocity imaging of the right coronary artery was performed in 7 asymptomatic premenopausal women with DM and 8 healthy female participants in response to the cold pressor test at 3 T. Results There was no significant difference in percent increase in coronary flow velocity from rest to peak flow velocity between DM and control subjects (32% ± 22% vs 46% ± 17%; P = 0.11). However, percent increase in coronary flow velocity was lower in DM than in control subjects (−3% ± 14% vs 31% ± 30%; P = 0.01) during the second minute of cold pressor stress, when endothelial-mediated vasodilation should occur. Conclusions Asymptomatic women with DM demonstrate reduced coronary flow velocity during the second minute of cold pressor stress, indicating coronary endothelial dysfunction.